BioSpace News Archive

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.

DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting.

Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 2,910,780 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET.

BioSyent Inc. released its financial results for the three months ended March 31, 2024.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share.

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies.

Seelos Therapeutics, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 380,968 shares of common stock and pre-funded warrants to purchase up to 81,239 shares of common stock at a price of $2.46 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Kane Biotech Inc. will release its first quarter 2024 financial results after market close on Thursday, May 23, 2024.

Oragenics, Inc. today announced an update on the company and its drug development program. Oragenics is designing an upcoming Phase II clinical trial conducted in acute and emergency departments.